Emerging options in development for treatment of filovirus infections

Drugs of the Future

Volumn 40, Issue 11, 2015, Pages 727-738

  Cardile, Anthony P ^a   Mayers, D L ^b   Bavari, S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Therapeutic Development Center   (United States)

Author keywords

Amodiaquine; Antisense phosphorodiamidate; BCX 4433; Brincidofovir; Convalescent plasma; Ebola; Favipiravir; FX 06; Interferon; Marburg; Morpholino oligomers; Recombinant nematode anticoagulant protein c2; Small interfering RNAs; ZMapp

Indexed keywords

AMIODARONE; AMODIAQUINE; ANTICOAGULANT PROTEIN; ANTIVIRUS AGENT; AVI 7537; BRINCIDOFOVIR; CHLOROQUINE; FAVIPIRAVIR; GALIDESIVIR; HYPERIMMUNE GLOBULIN; INTERFERON; NUCLEIC ACID; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; SMALL INTERFERING RNA; TKM EBOLA; UNCLASSIFIED DRUG; ZMAPP;

ANTIVIRAL ACTIVITY; ARTICLE; EBOLAVIRUS; EPIDEMIC; FILOVIRUS INFECTION; HUMAN; MARBURGVIRUS; NONHUMAN; PASSIVE IMMUNIZATION;

EID: 84983460598     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2015.040.11.2387219     Document Type: Article

References (109)

1. Dolnik, O., Kolesnikova, l., Becker, S. Filoviruses: Interactions with the host cell. Cell Mol life Sci 2008, 65(5): 756-76.
2. Baize, S., Pannetier, D., Oestereich, l. et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014, 371(15): 1418-25.
3. Kondratowicz, A.S., Maury, w.J. Ebolavirus: A brief review of novel therapeutic targets. Future Microbiol 2012, 7(1): 1-4.
4. Feldmann, H., Jones, S.M., Daddario-DiCaprio, K.M. et al. Effective postexposure treatment of Ebola infection. PloS Pathog 2007, 3(1): E2.
5. Harty, R.N. No exit: Targeting the budding process to inhibit filovirus replication. Antiviral Res 2009, 81(3): 189-97.
6. Friedrich, B.M., Trefry, J.C., Biggins, J.E., Hensley, l.E., Honko, A.N., Smith, D.R., Olinger, G.G. Potential vaccines and post-exposure treatments for filovirus infections. viruses 2012, 4(9): 1619-50.
7. Cardile, A.P., Mayers, D.l., Bavari, S. Current status of chemically synthesized inhibitors of ebola virus. Recent Pat Antiinfect Drug Discov 2014, 9(2): 97-103.
8. lai, K.Y., Ng, w.Y., Cheng, F.F. Human Ebola virus infection in West Africa: A review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty 2014, 3: 43.
9. Choi, w.Y., Hong, K.J., Hong, J.E., lee, w.J. Progress of vaccine and drug development for Ebola preparedness. Clin Exp vaccine Res 2015, 4(1): 11-6.
10. De Clercq, E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015, 93(1): 1-10.
11. Jadav, S.S., Kumar, A., Ahsan, M.J., Jayaprakash, v. Ebola virus: Current and future perspectives. Infect Disord Drug Targets 2015, 15(1): 20-31.
12. li, H., Ying, T., Yu, F., lu, l., Jiang, S. Development of therapeutics for treatment of Ebola virus infection. Microbes Infect 2015, 17(2): 109-17.
13. Nunes-Alves, C. Viral infection: New options to fight Ebola. Nat Rev Microbiol 2015, 13(6): 327.
14. Picazo, E., Giordanetto, F. Small molecule inhibitors of Ebola virus infection. Drug Discov Today 2015, 20(2): 277-86.
15. Shurtleff, A.C., whitehouse, C.A., ward, M.D., Cazares, l.H., Bavari, S. Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol 2015, 6: 108.
16. Jahrling, P.B., Hensley, l.E., Barrett, K., lane, H.C., Davey, R.T. State-ofthe- Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. J Infect Dis 2015, 212(Suppl. 2): S84-90.
17. world Health Organization (wHO). Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. http://www.who.int/medicines/ebola-treatment/cat-prioritization- drugs-testing/en/. Accessed July 23, 2015.
18. Falzarano, D., Feldmann, H. Possible leap ahead in filovirus therapeutics. Cell Res 2014, 24(6): 647-8.
19. Julander, J.G., Bantia, S., Taubenheim, B.R. et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother 2014, 58(11): 6607-14.
20. warren, T.K., wells, J., Panchal, R.G. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014, 508(7496): 402-5.
21. A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of BCX4430 (NCT02319772). ClinicalTrials.gov web site.
22. Hostetler, K.Y. Synthesis and early development of hexadecyloxypropylcidofovir: An oral antipoxvirus nucleoside phosphonate. viruses 2010, 2(10): 2213-25.
23. De Clercq, E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003, 16(4): 569-96.
24. lanier, R., Trost, l., Tippin, T. et al. Development of CMX001 for the Treatment of Poxvirus Infections. viruses 2010, 2(12): 2740-62.
25. Chimerix announces emergency Investigational New Drug Applications for brincidofovir authorized by FDA for patients with Ebola virus disease [news release]. Chimerix, Inc., October 16, 2014.
26. Florescu, D.F., Kalil, A.C., Hewlett, A.l., Schuh, A.J., Stroher, U., Uyeki, T.M., Smith, P.w. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis 2015, 61(6): 969-73.
27. Painter, w., Robertson, A., Trost, l.C., Godkin, S., lampert, B., Painter, G. First pharmacokinetic and safety study in humans of the novel lipid anti- viral conjugate CMX001, a broad-spectrum oral drug active against double- stranded DNA viruses. Antimicrob Agents Chemother 2012, 56(5): 2726-34.
28. Marty, F.M., winston, D.J., Rowley, S.D. et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013, 369(13): 1227-36.
29. Brincidofovir. Chimerix, Inc. web site, http://www.chimerix.com/discovery-clinical-trials/brincidofovir/. Accessed November 19, 2015.
30. Phase III, open-labeled, multicenter study of the safety and efficacy of brincidofovir (CMX001) in the treatment of early versus late adenovirus infection (NCT02087306). ClinicalTrials.gov web site.
31. Care of the patient with Ebola virus disease. Emory Healthcare, http://www.emoryhealthcare.org/ebola-protocol/pdf/overview-ofebola. pdf. Accessed November 19, 2015.
32. Chimerix focusing efforts on CMv and adenovirus pivotal trials [news release]. Chimerix, Inc., January 30, 2015.
33. Oestereich, l., ludtke, A., wurr, S., Rieger, T., Munoz-Fontela, C., Gunther, S. Successful treatment of advanced Ebola virus infection with T- 705 (favipiravir) in a small animal model. Antiviral Res 2014, 105: 17-21.
34. Caroline, A.l., Powell, D.S., Bethel, l.M., Oury, T.D., Reed, D.S., Hartman, A.l. Broad spectrum antiviral activity of favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever. PloS Negl Trop Dis 2014, 8(4): E2790.
35. Gowen, B.B., Smee, D.F., wong, M.H. et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS One 2008, 3(11): E3725.
36. Gowen, B.B., wong, M.H., Jung, K.H. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007, 51(9): 3168-76.
37. Gowen, B.B., wong, M.H., Jung, K.H., Smee, D.F., Morrey, J.D., Furuta, Y. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010, 86(2): 121-7.
38. Julander, J.G., Shafer, K., Smee, D.F., Morrey, J.D., Furuta, Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009, 53(1): 202-9.
39. Nyakatura, E.K., Frei, J.C., lai, J.R. Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infect Dis 2015, 1(1): 42-52.
40. Rocha-Pereira, J., Jochmans, D., Dallmeier, K., leyssen, P., Nascimento, M.S., Neyts, J. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 2012, 424(4): 777-80.
41. Smither, S.J., Eastaugh, l.S., Steward, J.A., Nelson, M., lenk, R.P., lever, M.S. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014, 104: 153-5.
42. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.l. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013, 100(2): 446-54.
43. Mentre, F., Taburet, A.M., Guedj, J., Anglaret, X., Keita, S., de lamballerie, X., Malvy, D. Dose regimen of favipiravir for Ebola virus disease. lancet Infect Dis 2015, 15(2): 150-1.
44. Bouazza, N., Treluyer, J.M., Foissac, F. et al. Favipiravir for children with Ebola. lancet 2015, 385(9968): 603-4.
45. wolf, T., Kann, G., Becker, S. et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: Treatment of a patient in intensive care. lancet 2015, 385(9976): 1428-35.
46. Avigan® Tablet 200mg administered to a French woman infected with Ebola virus [news release]. FUJIFIlM Corporation, September 26, 2014.
47. Brief Report: Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015, 372(25): 2469.
48. varkey, J.B., Shantha, J.G., Crozier, I. et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015, 372(25): 2423-7.
49. Mora-Rillo, M., Arsuaga, M., Ramirez-Olivencia, G. et al. Acute respiratory distress syndrome after convalescent plasma use: Treatment of a patient with Ebola virus disease contracted in Madrid, Spain. lancet Respir Med 2015, 3(7): 554-62.
50. Sissoko, D., Anglaret, X., Malvy, D., et al. Favipiravir in patients with Ebola virus disease: Early results of the JIKI trial in Guinea. 22nd Conf Retroviruses Opportunistic Infect (CROI) (February 23-26, Seattle) 2015, Abst 103-AlB.
51. world Health Organization (wHO). Table of drug clinical trials. http://www.who.int/medicines/ebola-treatment/ebola-drug- clinicaltrials/en/. Accessed July 23, 2015.
52. Kole, R., Krainer, A.R., Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012, 11(2): 125-40.
53. Spurgers, K.B., Sharkey, C.M., warfield, K.l., Bavari, S. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008, 78(1): 26-36.
54. Iversen, P.l., warren, T.K., wells, J.B. et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. viruses 2012, 4(11): 2806-30.
55. warren, T.K., whitehouse, C.A., wells, J. et al. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio 2015, 6(1).
56. Heald, A.E., Iversen, P.l., Saoud, J.B. et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: Results of two single-ascending-dose studies. Antimicrob Agents Chemother 2014, 58(11): 6639-47.
57. Heald, A.E., Charleston, J.S., Iversen, P.l. et al. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med 2015, 373(4): 339-48.
58. Kugelman, J.R., Sanchez-lockhart, M., Andersen, K.G. et al. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio 2015, 6(1).
59. Bray, M., Driscoll, J., Huggins, J.w. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000, 45(2): 135-47.
60. Cullen, B.R. Viruses and RNA interference: Issues and controversies. J virol 2014, 88(22): 12934-6.
61. Geisbert, T.w., lee, A.C., Robbins, M. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. lancet 2010, 375(9729): 1896-905.
62. Torrecilla, J., Rodriguez-Gascon, A., Solinis, M.A., del Pozo-Rodriguez, A. Lipid nanoparticles as carriers for RNAi against viral infections: Current status and future perspectives. Biomed Res Int 2014, 2014: 161794.
63. Geisbert, T.w., Hensley, l.E., Kagan, E. et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193(12): 1650-7.
64. Morrissey, D.v., lockridge, J.A., Shaw, l. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23(8): 1002-7.
65. Thi, E.P., Mire, C.E., lee, A.C. et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015, 521(7552): 362-5.
66. Kraft, C.S., Hewlett, A.l., Koepsell, S. et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015, 61(4): 496-502.
67. Judge, A.D., Sood, v., Shaw, J.R., Fang, D., McClintock, K., Maclachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23(4): 457-62.
68. Sioud, M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci 2008, 13: 4379-92.
69. TKM-Ebola. Ebola Clinical Trials web site, https://ebolaclinicaltrials. tghn.org/rapide-tkm-ebola-trial/. Accessed October 12, 2015.
70. Tekmira provides update on TKM-Ebola-Guinea [news release]. Arbutus Biopharma, June 19, 2015.
71. Tekmira announces launch of Arbutus Biopharma, a hepatitis B solutions company [news release]. Arbutus Biopharma Corp, July 20, 2015. Accessed
72. Ursic-Bedoya, R., Mire, C.E., Robbins, M., Geisbert, J.B., Judge, A., Maclachlan, I., Geisbert, T.w. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J Infect Dis 2014, 209(4): 562-70.
73. Thi, E.P., Mire, C.E., Ursic-Bedoya, R. et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med 2014, 6(250): 250ra116.
74. Casadevall, A., Pirofski, l.A. The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. PloS Pathog 2015, 11(4): E1004717.
75. Colebunders, R.l., Cannon, R.O. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 2015, 211(8): 1208-10.
76. Mupapa, K., Massamba, M., Kibadi, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999, 179(Suppl. 1): S18-23.
77. Enserink, M. Infectious diseases. Ebola survivors fight back in plasma studies. Science 2015, 348(6236): 742-3.
78. Jahrling, P.B., Geisbert, J., Swearengen, J.R. et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch virol Suppl 1996, 11: 135-40.
79. Jahrling, P.B., Geisbert, J.B., Swearengen, J.R., larsen, T., Geisbert, T.w. Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007, 196(Suppl. 2): S400-3.
80. Jahrling, P.B., Geisbert, T.w., Geisbert, J.B. et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999, 179(Suppl. 1): S224-34.
81. Kudoyarova-Zubavichene, N.M., Sergeyev, N.N., Chepurnov, A.A., Netesov, S.v. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 1999, 179(Suppl. 1): S218- 23.
82. Dye, J.M., Herbert, A.S., Kuehne, A.I. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012, 109(13): 5034-9.
83. Qiu, X., wong, G., Audet, J. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514(7520): 47-53.
84. lyon, G.M., Mehta, A.K., varkey, J.B. et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014, 371(25): 2402-9.
85. Mundasad, S. British medic declared free of Ebola. http://www.bbc.com/news/health-32088310. Accessed July 23, 2015.
86. Putative investigational therapeutics in the treatment of patients with known Ebola infection (NCT02363322). ClinicalTrials.gov web site, Accessed July 23, 2015.
87. Smith, l.M., Hensley, l.E., Geisbert, T.w. et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 2013, 208(2): 310-8.
88. Geisbert, T.w., Daddario-DiCaprio, K.M., Geisbert, J.B. et al. Marburg virus Angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007, 196 Suppl 2: S372-81.
89. Geisbert, T.w., Hensley, l.E., Jahrling, P.B. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. lancet 2003, 362(9400): 1953-8.
90. Bavari, S., Bosio, C.M., wiegand, E. et al. Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002, 195(5): 593-602.
91. Bhattacharyya, S., warfield, K.l., Ruthel, G., Bavari, S., Aman, M.J., Hope, T.J. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. virology 2010, 401(1): 18-28.
92. Madrid, P.B., Chopra, S., Manger, I.D. et al. A systematic screen of FDAapproved drugs for inhibitors of biological threat agents. PloS One 2013, 8(4): E60579.
93. Miller, M.E., Adhikary, S., Kolokoltsov, A.A., Davey, R.A. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J virol 2012, 86(14): 7473-83.
94. Sakurai, Y., Kolokoltsov, A.A., Chen, C.C. et al. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 2015, 347(6225): 995-8.
95. Yonezawa, A., Cavrois, M., Greene, w.C. Studies of ebola virus glycoprotein- mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: Involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J virol 2005, 79(2): 918-26.
96. Cheng, H., lear-Rooney, C.M., Johansen, l., varhegyi, E., Chen, Z.w., Olinger, G.G., Rong, l. Inhibition of Ebola and Marburg virus entry by G protein-coupled receptor antagonists. J virol 2015, 89(19): 9932-8.
97. Johansen, l.M., Dewald, l.E., Shoemaker, C.J. et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 2015, 7(290): 290ra89.
98. Patane, S. Ebola: Is there a hope from treatment with cardiovascular drugs? Int J Cardiol 2014, 177(2): 524-6.
99. Masters, A., Pandi-Perumal, S.R., Seixas, A., Girardin, J.l., McFarlane, S.I. Melatonin, the hormone of darkness: From sleep promotion to Ebola treatment. Brain Disord Ther 2014, 4(1).
100. Tan, D.X., Korkmaz, A., Reiter, R.J., Manchester, l.C. Ebola virus disease: Potential use of melatonin as a treatment. J Pineal Res 2014, 57(4): 381-4.
101. Hensley, l.E., Dyall, J., Olinger, G.G., Jr., Jahrling, P.B. Lack of effect of lamivudine on Ebola virus replication. Emerg Infect Dis 2015, 21(3): 550-2.
102. Fedson, D.S. Immunomodulatory adjunctive treatment options for Ebola virus disease patients: Another view. Intensive Care Med 2015, 41(7): 1383.
103. Fedson, D.S., Jacobson, J.R., Rordam, O.M., Opal, S.M. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio 2015, 6(3): E00716.
104. Fedson, D.S., Rordam, O.M. Treating Ebola patients: A 'bottom up' approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015, 36: 80-4.
105. Gehring, G., Rohrmann, K., Atenchong, N. et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014, 69(8): 2123-31.
106. Salata, C., Baritussio, A., Munegato, D. et al. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog Dis 2015, 73(5).
107. Turone, F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 2014, 349: G7198.
108. Johansen, l.M., Brannan, J.M., Delos, S.E. et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013, 5(190): 190ra79.
109. Falzarano, D., Safronetz, D., Prescott, J., Marzi, A., Feldmann, F., Feldmann, H. Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis 2015, 21(6): 1065-7.